A Phase 1, Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of SNDX-6352 in Subjects With Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Prior Therapy
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2019
Price : $35 *
At a glance
- Drugs UCB 6352 (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- Sponsors Syndax Pharmaceuticals
- 04 Dec 2019 Planned number of patients changed from 132 to 30.
- 13 Nov 2019 Planned number of patients changed from 30 to 132.
- 13 Nov 2019 Planned End Date changed from 1 Mar 2020 to 1 Dec 2020.